Author Index

Adera T, 302
Amos NE, 407
Atkin CL, 73

Bally SJ, 311
Baran JA, 211
Barlow SM, 163
Beauchaine KL, 150
Behrens TR, 271
Bergman BM, 150
Bielek D, 225
Bornstein SP, 293
Brandt F, 311
Brey RH, 243
Brookhouser PE, 163
Bryant K, 334
Bull MJ, 39
Butcher JA, 346
Byrne D, 129

Calder JH, 425
Carter J, 197
Casey-Harvey D, 39
Catherwood KP, 211
Cevette MJ, 197, 225
Clarke-Klein SM, 230
Coppage KB, 103
Cox LC, 261
Crandell CC, 414
Crawford MR, 278
Cunningham D, 111

Davis A, 365
Davis K, 230
Davis-Thaxton ML, 330
Dickinson WW, 425
Diefendorf AO, 39
Dodson S, 278

Epstein L, 371

Fabry DA, 440
Facer GW, 243, 264
Ferraro JA, 217
Firszt JB, 235
Fortin M, 378
Fowler B, 398
Fowler CG, 399

Gardner JW, 302
Ge X, 256
Gelfand SA, 141
Gerber SE, 371
Goebel J, 203
Gorga MP, 150, 163
Gould HJ, 278
Gregory MC, 73
Gullickson GM, 302
Gulliver M, 351
Gustafson TJS, 124

Hall JW III, 80
Hamill TA, 124
Healy R, 365
Helfer T, 302
Herrera G, 358
Hétu R, 378
Hurley RM, 398

Jacobson GP, 346
Jacobson JT, 15, 28, 93
Jahrsdoerfer RA, 93
Jerger J, 330

Kaminski JR, 150
Kaplan H, 311
Kasperbauer JL, 264
Keith RW, 286
Kileny PR, 111
Kimberling WJ, 63
Knops JL, 197

Letowski T, 433
Lynn SG, 264

MacDonald CB, 261
Madriz JJ, 358
Mahoney T, 398
Maxon AB, 271
McDaniel DM, 173
Medley L, 230
Mencher GT, 351
Mencher L, 351, 371
Mendel MI, 278
Mikami CM, 399
Miyamoto RT, 39
Möller C, 63
Monsell EM, 346
Montano J, 250
Morr ML, 396
Mundy M, 334
Musiek FE, 211, 293

Needleman AR, 414
Neely JG, 203
Neely ST, 150
Nerbonne MA, 183
Newman CW, 346
Ninya RL, 183
Noble W, 129
Novak MA, 235
Novotny G, 351

Orchik DJ, 256

Parving A, 387
Peck JE, 113
Peterein J, 203
Peters J, 150
Peterson AM, 243
Pikus AT, 54

Poch N, 433
Pope ML, 39
Potts LG, 440
Prentice CH, 80
Punch JL, 425

Reeder RM, 235
Renshaw JJ, 39
Richards AM, 250
Rintelmann WF, 293
Roberts J, 230, 334
Robinette MS, 197
Rourke-Cullen T, 183
Roush J, 230, 334
Roush PA, 187
Rowe S, 365

Schreiner RL, 39
Schumaier DR, 256
Segal AI, 191
Sells JP, 398
Shea JJ Jr., 256
Sherbecoe RL, 173
Shovels AH, 425
Silman S, 193, 339
Silverman CA, 339
Simpson TH, 407
Smiley G, 80
Smith RJH, 103
Smith SD, 1
Snead C, 425
Stach BA, 330
Stelmachowicz PG, 163
Strasnick B, 28
Studebaker GA, 173

Ter-Horst K, 129
Toriello HV, 47
Trine MB, 264
Trouba SE, 217

Valente M, 203, 440
Vohr BR, 271

Wagner-Escobar M, 39
Wang L, 302
Webb H, 365
Weber BA, 187
Weinstein BE, 250
Werkhaven J, 80
Wester DC, 73
White KR, 271
Widen JE, 217
Windmill IM, 111
Wood S, 365

Zeisel S, 334

Subject Index

Abbreviated Profile of Hearing Aid Benefit (APHAB), 440–448
ABR. *See* Auditory brainstem response
Acoustic immittance, 334–338
Acoustic neuromas, 203–209, 396–398
Acquired immune deficiency syndrome. *See* AIDS
AEP. *See* Auditory evoked potential
AEVs. *See* Averaged electrode voltages
AI. *See* Articulation index
AIDS (acquired immune deficiency syndrome), related hearing disorders, 358–362
Alcohol, 371–373
Alport syndrome, 73–78
  genetics of, 74
  hearing loss in, 75–76
  prevalence of, 73
  vestibular function in, 75
ALRs. *See* Auditory late potentials
American National Standards Institute (ANSI), 302–310, 407–413
American Speech-Language-Hearing Association (ASHA), 183
Aminoglycosides, 35
Amplification, 98–99, 230–233
  binaural, 141–148
Amplified music exposure, 378–384
ANSI. *See* American National Standards Institute
APHAB. *See* Abbreviated Profile of Hearing Aid Benefit
Articulation index (AI), 173–182
ASHA. *See* American Speech-Language-Hearing Association
Atresia choanae, 48
Audible popping sounds, 261–263
Audiometric database analysis, 302–310
Auditec recordings, 183–186
Auditory brainstem response (ABR)
  acoustic neuromas and, 203–209
  binaural phase effects in, 399–406
  in brainstem tumor, 211–216

Author Index

Adera T, 302
Amos NE, 407
Atkin CL, 73

Bally SJ, 311
Baran JA, 211
Barlow SM, 163
Beauchaine KL, 150
Behrens TR, 271
Bergman BM, 150
Bielek D, 225
Bornstein SP, 293
Brandt F, 311
Brey RH, 243
Brookhouser PE, 163
Bryant K, 334
Bull MJ, 39
Butcher JA, 346
Byrne D, 129

Calder JH, 425
Carter J, 197
Casey-Harvey D, 39
Catherwood KP, 211
Cevette MJ, 197, 225
Clarke-Klein SM, 230
Coppage KB, 103
Cox LC, 261
Crandell CC, 414
Crawford MR, 278
Cunningham D, 111

Davis A, 365
Davis K, 230
Davis-Thaxton ML, 330
Dickinson WW, 425
Diefendorf AO, 39
Dodson S, 278

Epstein L, 371

Fabry DA, 440
Facer GW, 243, 264
Ferraro JA, 217
Firszt JB, 235
Fortin M, 378
Fowler B, 398
Fowler CG, 399

Gardner JW, 302
Ge X, 256
Gelfand SA, 141
Gerber SE, 371
Goebel J, 203
Gorga MP, 150, 163
Gould HJ, 278
Gregory MC, 73
Gullickson GM, 302
Gulliver M, 351
Gustafson TJS, 124

Hall JW III, 80
Hamill TA, 124
Healy R, 365
Helfer T, 302
Herrera G, 358
Hétu R, 378
Hurley RM, 398

Jacobson GP, 346
Jacobson JT, 15, 28, 93
Jahrsdoerfer RA, 93
Jerger J, 330

Kaminski JR, 150
Kaplan H, 311
Kasperbauer JL, 264
Keith RW, 286
Kileny PR, 111
Kimberling WJ, 63
Knops JL, 197

Letowski T, 433
Lynn SG, 264

MacDonald CB, 261
Madriz JJ, 358
Mahoney T, 398
Maxon AB, 271
McDaniel DM, 173
Medley L, 230
Mencher GT, 351
Mencher L, 351, 371
Mendel MI, 278
Mikami CM, 399
Miyamoto RT, 39
Möller C, 63
Monsell EM, 346
Montano J, 250
Morr ML, 396
Mundy M, 334
Musiek FE, 211, 293

Needleman AR, 414
Neely JG, 203
Neely ST, 150
Nerbonne MA, 183
Newman CW, 346
Ninya RL, 183
Noble W, 129
Novak MA, 235
Novotny G, 351

Orchik DJ, 256

Parving A, 387
Peck JE, 113
Peterein J, 203
Peters J, 150
Peterson AM, 243
Pikus AT, 54

Poch N, 433
Pope ML, 39
Potts LG, 440
Prentice CH, 80
Punch JL, 425

Reeder RM, 235
Renshaw JJ, 39
Richards AM, 250
Rintelmann WF, 293
Roberts J, 230, 334
Robinette MS, 197
Rourke-Cullen T, 183
Roush J, 230, 334
Roush PA, 187
Rowe S, 365

Schreiner RL, 39
Schumaier DR, 256
Segal AI, 191
Sells JP, 398
Shea JJ Jr., 256
Sherbecoe RL, 173
Shovels AH, 425
Silman S, 193, 339
Silverman CA, 339
Simpson TH, 407
Smiley G, 80
Smith RJH, 103
Smith SD, 1
Snead C, 425
Stach BA, 330
Stelmachowicz PG, 163
Strasnick B, 28
Studebaker GA, 173

Ter-Horst K, 129
Toriello HV, 47
Trine MB, 264
Trouba SE, 217

Valente M, 203, 440
Vohr BR, 271

Wagner-Escobar M, 39
Wang L, 302
Webb H, 365
Weber BA, 187
Weinstein BE, 250
Werkhaven J, 80
Wester DC, 73
White KR, 271
Widen JE, 217
Windmill IM, 111
Wood S, 365

Zeisel S, 334

Subject Index

Abbreviated Profile of Hearing Aid Benefit (APHAB), 440–448
ABR. *See* Auditory brainstem response
Acoustic immittance, 334–338
Acoustic neuromas, 203–209, 396–398
Acquired immune deficiency syndrome. *See* AIDS
AEP. *See* Auditory evoked potential
AEVs. *See* Averaged electrode voltages
AI. *See* Articulation index
AIDS (acquired immune deficiency syndrome), related hearing disorders, 358–362
Alcohol, 371–373
Alport syndrome, 73–78
  genetics of, 74
  hearing loss in, 75–76
  prevalence of, 73
  vestibular function in, 75
ALRs. *See* Auditory late potentials
American National Standards Institute (ANSI), 302–310, 407–413
American Speech-Language-Hearing Association (ASHA), 183
Aminoglycosides, 35
Amplification, 98–99, 230–233
  binaural, 141–148
Amplified music exposure, 378–384
ANSI. *See* American National Standards Institute
APHAB. *See* Abbreviated Profile of Hearing Aid Benefit
Articulation index (AI), 173–182
ASHA. *See* American Speech-Language-Hearing Association
Atresia choanae, 48
Audible popping sounds, 261–263
Audiometric database analysis, 302–310
Auditec recordings, 183–186
Auditory brainstem response (ABR)
  acoustic neuromas and, 203–209
  binaural phase effects in, 399–406
  in brainstem tumor, 211–216

electrical, 235–241
hearing loss and, 80–92, 163–171, 217–224
maximum length sequence analysis and, 187–190
in multiple sclerosis, 193–196
neurofibromatosis and, 54–61
in traumatic brain injury, 225–228
Auditory deprivation effect, 141–148
Auditory dysfunction. *See* Hearing loss
Auditory evoked potential (AEP), 217–224
Auditory late potentials (ALRs), 163–171
Autosomal-dominant inheritance, 18
Autosomal-recessive inheritance, 17–18
Averaged electrode voltages (AEVs)
in cochlear implants, 243–249
inner ear malformation and, 235–241

Babies. *See* Infants
Bacterial infections, 33
Benign paroxysmal positioning vertigo, 346–349
Binaural amplification, 141–148
Binaural interference, in multiple sclerosis, 193–196
Binaural phase effects, in ABR, 399–406
BOF syndrome. *See* Branchio-oculo-facial (BOF) syndrome
Bone–conduction threshold, 256–260
BOR syndrome. *See* Branchio-oto-renal (BOR) syndrome
Brain injury, 225–228
Brainstem tumor, 211–216
Branchial arch syndrome, 108
Branchio-oculo-facial (BOF) syndrome, 107
Branchio-oto-renal (BOR) syndrome, 82, 103–109

Carpenter syndrome, 82, 87, 88–89
Central nervous system, 360–361
CHARGE association, 47–52
Chemical agents. *See* Drugs
Chemotherapy, 351–356
Chernobyl nuclear accident, 351–356
Children
hearing loss in, 28–36, 365–370, 387–392
with middle-ear effusion, 339–345
neurofibromatosis in, 54–61
reversible hearing loss in, 163–171
See also Infants
Chloroquine, 35
Chromosomal aberrations, 19
CID W-1 word list, 183–186
Cisplatin, 351–356
CMV. *See* Cytomegalovirus
Cocaine, 373–374
Cochlear implant
averaged electrode voltages in, 243–249
multichannel, 235–241
Collagen, 6–7
Coloboma, 47
Communication Self–assessment Scale Inventory for Deaf Adults (CSDA), 311–329
Computer-based speech, 330–333
Conductive hearing loss, 124–127, 359–360
Congenital hearing loss, 21–25, 28–36
Connective tissue, 6–8
Conversational discourse skills, 230–233
Craniofacial disorders, 5–6
CSDA. *See* Communication Self-assessment Scale Inventory for Deaf Adults
Cytomegalovirus (CMV), 32–33

Deafness. *See* Hearing loss
Developmental retardation, 48
Diabetes mellitus, 393
Directional microphone, 440–448
Disabilities
and impaired auditory localization, 129–140
vs. impairment, 250–255
Discard interval, 433–439
Discotheque music, 378–384
Discrimination, neonate, 118
Distortion-product otoacoustic emissions (DPOAEs)
from intensive care nursery graduates, 150–161
in traumatic brain injury, 225–228
Dominant progressive hearing loss, 11
Down syndrome, 39–45
genetics, 39–40
hearing loss and, 41–42
language and speech disorders, 44–45
outer and middle ear anomalies, 40–41
DPOAEs. *See* Distortion-product otoacoustic emissions
Drugs
nonprescription, 34–35
perinatal exposure to, 371–375
prescription, 34–35
See also specific drugs

EABR. *See* Electrical auditory brainstem response
Ear
anomalies, 48–49, 95
canal, 261–263
inner, 235–241, 256–260
middle, 256–260
See also Hearing; Real-ear coupler difference
Electrical auditory brainstem response (EABR), 235–241
Electrocochleography, 168–169
Electroneurography (ENOG), 203–209
Electronystagmography (ENG), 211–216, 346–349
Embryo, 28–29
Endocrine gland disorders, 392–393
ENG. *See* Electronystagmography
ENOG. *See* Electroneurography
EOAEs. *See* Evoked otoacoustic emissions
Equivalence classification, 118–119
Estimated noise distributions, 278–285
Ethyl alcohol, 34–35
Evoked otoacoustic emissions (EOAEs), 197–201, 217–224
External ear, HIV/AIDS and, 359–360

Facial nerve, 166–167
FM amplification, 230–233
Fsp quantification technique, 278–285

Gender, 407–413
Genetics, 36
Alport syndrome, 74
auditory syndromes, 1–12
Down syndrome, 39–40
mutation, 17
Usher syndrome, 63–72
Genital anomalies, 48
Gentamicin, 264–270
Goldenhar syndrome. *See* Oculo-auriculo-vertebral (OAV) dysplasia
Growth retardation, 48

Handicaps. *See* Disabilities
Hearing
discrimination, 118
infants', 113–121, 191, 271–277
localization, 115–116, 124–127, 129–140
recognition, 116–118
sensitivity, 114–115
Hearing aids
speech recognition with, 440–448
target-matched insertion gain from, 425–432
Hearing conservation program (HCP), 302–310, 407–413
Hearing in Noise Test (HINT), 440–448
Hearing loss
in Alport syndrome, 75–76
causes of, 387–393
in children, 28–36, 365–370, 387–392
classification of, 15–25
conductive, 124–127, 359–360
congenital, 21–25, 28–36
Down syndrome and, 41–42
from amplified music exposure, 378–384
from prenatal drug exposure, 371–375
handicaps from, 129–140, 250–255
HIV and AIDS related, 358–362
inherited, 16–17
nonsyndromic, 10–11
pre-existing, 407–413
progressive neural, 217–224
in selected syndromes, 80–92
sudden unilateral, 197–201
teratogenic, 28–36
See also Sensorineural hearing loss
Hearing threshold level (HTL), 407–413
Heart defects, 48
Hemifacial microsomia. *See* Oculo-auriculo-vertebral (OAV) dysplasia
HINT. *See* Hearing in Noise Test
HIV (human immunodeficiency virus), related hearing disorders, 358–362
HTL. *See* Hearing threshold level
Human immunodeficiency virus. *See* HIV
Hypothyroidism, 392–393

Ichthyosiform dermatosis, 89–90
ICN. *See* Intensive care nursery
Impairment. *See* Hearing loss
Infants
acoustic immittance in, 334–338
hearing screening, 191, 271–277
intensive care nursery graduates, 150–161
maximum length sequence analysis for, 187–190
postnatal hearing development, 113–121
teratogenic hearing loss, 28–36
Infections, 30–34
bacterial, 33
viral, 30–31, 33

Inherited hearing loss, 16–17
Inner ear
  effects on bone-conduction threshold, 256–260
  malformation, 235–241
Insertion gain, 425–432
Intensive care nursery (ICN), graduates from, 150–161
Internal ear, HIV/AIDS and, 360–361
Intratympanic gentamicin treatment, 264–270
Irradiation, 351–356

Language
  categories of, 118–119
  Down syndrome and, 44–45
Localization
  in conductive hearing loss, 124–127
  disabilities, 129–140
  postnatal, 115–116
LSD (lysergic acid diethylamide), 374–375

Malformation
  inner ear, 235–241
  patterns, 80–92
Mandibulofacial dysostosis. *See* Treacher Collins syndrome
Masking level difference (MLD), 399–406
Maternal metabolism, 36
Maximum length sequence analysis (MLSA), 187–190
Medications. *See* Drugs
MEE. *See* Middle-ear effusion
Meniere's disease, 264–270
Microphones, 440–448
Middle ear
  Down syndrome and, 40–41
  effects on bone-conduction threshold, 256–260
  HIV/AIDS and, 359–360
Middle-ear effusion (MEE), 339–345
Middle latency response (MLR)
  Fsp technique for, 278–285
  hearing loss and, 163–171, 217–224
  in multiple sclerosis, 193–196
Mitochondrial DNA, 8–9
MLD. *See* Masking level difference
MLR. *See* Middle latency response
MLSA. *See* Maximum length sequence analysis
MLV. *See* Monitored live voice
Molecular genetics. *See* Genetics
Monitored live voice (MLV), 183–186
Monosyllabic word tests, 175–177
MS. *See* Multiple sclerosis
Multichannel cochlear implant, 235–241
Multifactorial inheritance, 19–20
Multiple sclerosis (MS)
  binaural interference in, 193–196
  sudden unilateral hearing loss in, 197–201
Music, amplified, 378–384
Mutation, 17

Neonatal intensive care unit (NICU), 187–190
Neonatal ventilation, 398
Neurofibromatosis
  type 1, 54–57
  type 2, 54, 57–61
Neuromas, 203–209, 396–398
Neuromuscular disorders, 9–10
Newborns. *See* Infants
NF1. *See* Type 1 neurofibromatosis
NF2. *See* Type 2 neurofibromatosis
NICU. *See* Neonatal intensive care unit
Noise
  distributions, 278–285
  speech recognition in, 414–422, 440–448
Nonprescription drugs, 34–35
Nystagmus, positional, 346–349

OAEs. *See* Otoacoustic emissions
OAV dysplasia. *See* Oculo-auriculo-vertebral (OAV) dysplasia
Oculo-auriculo-vertebral (OAV) dysplasia, 107
Older adults, 433–439
Otoacoustic emissions (OAEs)
  hearing loss and, 169–170, 217–224
  from intensive care nursery graduates, 150–161
  in multiple sclerosis, 197–201
  in traumatic brain injury, 225–228
Otomandibular dysostosis, 107
Ototoxicity, 351–356
Outer ear anomalies, 40–41

Parasites, 33
Paroxysmal positioning vertigo, 346–349
PCP (phenylcyclidine), 374–375
Pediatrics. *See* Children; Infants
Pendred syndrome, 8
Perinatal drug exposure, 371–375
PHAB. *See* Profile of Hearing Aid Benefit
Phonemes, 118
Physical agents, and fetus, 36
Pigmentary/neural crest, 3–5
Popping sounds, 261–263
Positional nystagmus, 346–349
Postnatal drug effects, 375
Postnatal hearing development, 113–121
Prescription drugs, 34–35
Proficiency factor, 173–182
Profile of Hearing Aid Benefit (PHAB), 440–448
Progressive neural hearing loss, 217–224
Proteoglycans, 7–8
Pseudohypacusis, 293–301

Rationalized arcsine differences, 173–182
Real-ear coupler difference (RECD), 425–432
RECD. *See* Real-ear coupler difference
Recognition
  infant, of vocalizations, 116–118
  See also Speech, recognition
Retinitis pigmentosa (RP), 63–72
Retrocochlear anomalies, 41
Rhode Island Hearing Assessment Program (RIHAP), 271–277
RIHAP. *See* Rhode Island Hearing Assessment Program
RP. *See* Retinitis pigmentosa
Rubella, 31–32

SCAN-A test, 286–292
Sensitivity, 114–115
Sensorineural hearing loss (SNHL)
  auditory deprivation effect and, 141–148
  in child, 163–171
  HIV/AIDS and, 360–361
  neonatal ventilation and, 398
  speech recognition in, 414–422
Signal-to-noise ratio (SNR), 440–448
Single gene mutation, 17
SNHL. *See* Sensorineural hearing loss
SNR. *See* Signal-to-noise ratio
Speech
  computer-based, 330–333
  Down syndrome and, 44–45
  recognition, 173–182, 414–422, 440–448
  time-compressed, 433–439
Speech Perception in Noise test, 414–422
Static admittance, in toddlers and infants, 334–338
Storage disorders, 7–8
Sudden sensorineural hearing loss, 163–171
Sudden unilateral hearing loss, 197–201
Syphilis, 33

TCS. *See* Treacher Collins syndrome
Temporary threshold shift (TTS), 111
TEOAEs. *See* Transient-evoked otoacoustic emissions
Teratogenic hearing loss, 28–36
Teratology, 29–30
Thalidomide, 34
Time-compressed speech, 433–439
Toddlers, acoustic immittance in, 334–338
Townes-Brock syndrome, 86, 87, 90–91, 107
Toxoplasmosis, 33–34
Transient-evoked otoacoustic emissions (TEOAEs)
  from intensive care nursery graduates, 150–161
  newborn screening program using, 271–277
  pseudohypacusis and, 293–301
  in traumatic brain injury, 225–228
Traumatic brain injury, 225–228
Treacher Collins syndrome (TCS), 86, 93–101, 107
Trigeminal nerve, 166–167
Trisonomy 21. *See* Down syndrome
TTS. *See* Temporary threshold shift
Tumor, 211–216
Tympanometric peak pressure, 339–345
Tympanometric width
  in children, 339–345
  in toddlers and infants, 334–338
Type 1 neurofibromatosis (NF1), 54–57
Type 2 neurofibromatosis (NF2), 54, 57–61

Universal newborn hearing screening program, 271–277
Usher syndrome
  characteristics of, 64–66
  genetics of, 63–72
  inheritance pattern of, 69–70
  vestibular function in, 66–68

Vertigo, benign paroxysmal positioning, 346–349
Vestibular function
  in Alport syndrome, 75
  in Usher syndrome, 66–68
Viral infections, 30–31, 33
Voice
  infant recognition of, 116–118
  monitored live, 183–186

Waardenburg syndrome, 3–5
Word tests, 175–177

X-linked inheritance, 18–19